Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the first quarter.
Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.
DaVita HealthCare (DVA) concluded the recent trading session at $132.77, signifying a +0.02% move from its prior day's close.